NCT00137839

Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung

A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (actual)
• Sponsor: Pasi A. Janne, MD, PhD · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this trial is to figure out what effects (good or bad) the investigational drug agent called Tarceva (erlotinib; OSI-774) has on women with previously untreated adenocarcinoma.

Detailed description

Patients will start taking Tarceva daily by mouth on Day 1 and will continue taking this medication daily at home, until participation in the study ends.

Conditions

• Adenocarcinoma
• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Erlotinib

Timeline

• Start date: 2004-11-01
• Primary completion: 2008-11-01
• Completion: 2019-07-01
• First posted: 2005-08-30
• Last updated: 2019-12-17
• Results posted: 2019-11-22

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study